Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Argan (AGX) Current Deferred Revenue: 2018-2025

Historic Current Deferred Revenue for Argan (AGX) over the last 8 years, with Jan 2025 value amounting to $299.2 million.

  • Argan's Current Deferred Revenue rose 66.95% to $451.9 million in Q4 2025 from the same period last year, while for Oct 2025 it was $451.9 million, marking a year-over-year increase of 66.95%. This contributed to the annual value of $299.2 million for FY2025, which is 65.28% up from last year.
  • According to the latest figures from FY2025, Argan's Current Deferred Revenue is $299.2 million, which was up 65.28% from $181.1 million recorded in FY2024.
  • In the past 5 years, Argan's Current Deferred Revenue ranged from a high of $299.2 million in FY2025 and a low of $96.3 million during FY2023.
  • For the 3-year period, Argan's Current Deferred Revenue averaged around $192.2 million, with its median value being $181.1 million (2024).
  • Per our database at Business Quant, Argan's Current Deferred Revenue surged by 136.70% in 2021 and then decreased by 25.66% in 2022.
  • Yearly analysis of 5 years shows Argan's Current Deferred Revenue stood at $172.0 million in 2021, then dropped by 25.66% to $127.9 million in 2022, then decreased by 24.73% to $96.3 million in 2023, then spiked by 88.09% to $181.1 million in 2024, then spiked by 65.28% to $299.2 million in 2025.